Last quarter (Q4 2023), Can-Fite BioPharma's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, Can-Fite BioPharma's net income was $―. See Can-Fite BioPharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 408.00K	$ 743.00K	$ 810.00K	$ 853.00K	$ 763.00K	$ 2.03M
Cost of Revenue	-	-	$ -10.00K	-	-	-
Gross Profit	-	$ 743.00K	$ 810.00K	$ 853.00K	$ 763.00K	$ 2.03M
Operating Expense	$ 5.05M	$ 8.94M	$ 10.91M	$ 13.70M	$ -14.90M	$ -14.04M
Operating Income	$ -4.64M	$ -8.20M	$ -10.10M	$ -12.84M	$ -14.14M	$ -12.01M
Net Non Operating Interest Income Expense	$ -77.00K	$ 503.00K	$ -77.00K	$ 227.00K	$ -304.00K	$ -618.00K
Other Income Expense	-	-	-	$ -162.00K	-	$ -427.00K
Pretax Income	$ -4.72M	$ -7.63M	$ -10.17M	$ -12.62M	$ -14.44M	$ -12.63M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -4.72M	$ -7.63M	$ -10.17M	$ -15.21M	$ -15.16M	$ -12.63M
Basic EPS	$ -2.10	$ -0.01	$ -0.01	-	-	$ 26.73M
Diluted EPS	$ -2.10	$ -0.01	$ -0.01	$ -0.30	$ -0.40	$ -1.40
Basic Average Shares	$ 5.44M	$ 1.28B	$ 815.75M	$ 55.31M	$ 35.84M	$ 8.59M
Diluted Average Shares	$ 5.44M	$ 1.28B	$ 815.75M	$ 42.05M	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 5.05M	$ 8.94M	$ 10.90M	$ 13.70M	-	-
Net Income From Continuing And Discontinued Operation	$ -4.72M	$ -7.63M	$ -10.17M	$ -12.62M	$ -14.44M	$ -12.63M
Normalized Income	$ -4.72M	-	-	-	-	-
Interest Expense	-	-	-	-	-	-
EBIT	$ -4.64M	-	$ -10.17M	$ -12.84M	-	-
EBITDA	$ -4.64M	-	$ -10.16M	$ -12.83M	-	-

Currency in USD

Can-Fite BioPharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing